Innovus Pharmaceuticals Launches New Incontinence Product

Innovus Pharmaceuticals Launches New Incontinence Product

By: Dylan Sikes - AllPennyStocks.com News

Thursday, December 1, 2016

The pharmaceuticals industry is on track to reverse from a long downtrend and regain its credibility and valuations, following numerous debacles this year. Various issues ranging from drug pricing to failed trials marred the entire sector for the most part. The industry is also likely to benefit from potential sops, expected to be offered by the upcoming Trump administration. Micro and nano-cap stocks are likely to join the rally as well. Innovus Pharmaceuticals, Inc. . (OTCQB:INNV) is one such company, which has taken a number of positive steps to solidify its position in the market.


Innovus introduced its new product UriVarx™, which is designed to help people suffering from overactive bladder and urinary Incontinence. Through its mechanism of action, the drug helps by reducing urinary urgency and accidents. The product is designed for day and night use.
UriVarx™ is the fifth product to be launched using Innovus’ Beyond Human® sales and marketing platform. Not exactly a blockbuster, the company still expects the product to generate $3 million in revenue. CEO Dr. Bassam Damaj said that the product will help the company in reaching its target revenue of $15 million in 2017.

Dr. Damaj added, “Bladder health affects millions of people in the U.S. and we believe it is important to offer a natural, yet clinically tested alternative.” The product was tested using two double blind and comparative trials in both male and female OAB (overactive bladder) and UI (urge incontinence) patients. The tests showed that UriVarx™ resulted in 56% reduction in urge incontinence while stress incontinence was reduced by 66%. It also reduced urinary urgency and urinary frequency by 61% and 33%, respectively.

Per Simon Foundation, UI is a $1.1 billion strong market in the United States, while the National Association for Continence estimates the market for overactive bladder products to be at $2.1 billion. With the introduction of UriVarx™, Innovus Pharmaceuticals is in a strong position to capture a significant share of the market, even if it is wisely keeping its expectations tempered.

Apart from this development, the company is also boosting its supply chain. It recently announced inking a new deal with J&H Co. Ltd. The deal pertains to an exclusive license and distribution agreement for the commercialization of Zestra® in South Korea. This 10-year collaboration stipulates a minimum of $2 million per year in sales to Innovus for a total of $20 million over the life of the agreement.

The deal also marked the company’s 15th international deal. Innovus is looking to continue expanding the market for its products outside the U.S. The company stock has received a $1.00 price target from SeeThruEquity, an independent equity research firm. The target is mainly attributed to strong third quarter numbers shown by the firm. Innovus revenues rose by 947% YoY to reach $1.9 million.

Shares of INNV closed Thursday at $0.25, up 0.79%, with about 312,000 in volume.

Copyright © 2016 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Unexpected Copper Concentration Sends Shares of this Junior Miner Higher
Biotech Steals The Show Following Pre-Clinical Data Announcement
Micro Cap Up Big Following Acquisition Rumor
Most Popular
FREE Newsletter


Back to Top